Literature DB >> 25377270

Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case.

Tetsuya Isaka1,2, Tomoyuki Yokose3, Hiroyuki Ito4, Naoko Imamura4, Masato Watanabe4, Kentaro Imai4, Teppei Nishii4, Kouzo Yamada5, Haruhiko Nakayama4, Munetaka Masuda6.   

Abstract

We report a case of metachronous multiple lung adenocarcinoma at the cut-end, diagnosed 4 years after sublobar resection for adenocarcinoma in situ (AIS), on the basis of discordance of epidermal growth factor receptor (EGFR) mutation status between the first and second tumor. The patient was an 81-year-old Japanese man, whose chest computer tomography (CT) scan showed mixed ground-glass opacity in the right upper lobe of the lung. Wedge resection was performed and a diagnosis of AIS, non-mucinous (18 × 14 mm), with a margin of 6 mm, was made. A tumor at the cut-end was seen on a CT scan 4 years later, and abnormal uptake was identified by fluorine-18 fluorodeoxyglucose-positron emission tomography. Right upper lobectomy and lymph node dissection were performed and the tumor was diagnosed as invasive adenocarcinoma, acinar predominant. Discordance of EGFR mutation status between the first tumor, harboring exon 19 deletion, and the second tumor, having an L858R point mutation in exon 21, revealed that the second tumor was metachronous multiple lung cancer. This case demonstrates the necessity of comparing EGFR mutation status between the first tumor and the second tumor at the cut-end.

Entities:  

Keywords:  Cut-end; Discordance; EGFR mutation; Metachronous multiple lung cancer; Sublobar resection

Mesh:

Substances:

Year:  2014        PMID: 25377270     DOI: 10.1007/s00595-014-1077-z

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  18 in total

1.  Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules.

Authors:  Masayuki Nakao; Junji Yoshida; Koichi Goto; Genichiro Ishii; Akikazu Kawase; Keiju Aokage; Tomoyuki Hishida; Mitsuyo Nishimura; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

2.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Authors:  Yasushi Yatabe; Keitaro Matsuo; Tetsuya Mitsudomi
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

3.  Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients.

Authors:  Junji Yoshida; Genichiro Ishii; Tomoyuki Yokose; Keiju Aokage; Tomoyuki Hishida; Mitsuyo Nishimura; Takuya Onuki; Masayuki Noguchi; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Authors:  Yelena Y Janjigian; Bernard J Park; Maureen F Zakowski; Marc Ladanyi; William Pao; Sandra P D'Angelo; Mark G Kris; Ronglai Shen; Junting Zheng; Christopher G Azzoli
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

Review 6.  EGFR mutations and the terminal respiratory unit.

Authors:  Yasushi Yatabe
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

7.  A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).

Authors:  Koichi Goto; Makoto Nishio; Noboru Yamamoto; Kenichi Chikamori; Toyoaki Hida; Makoto Maemondo; Nobuyuki Katakami; Toshiyuki Kozuki; Hiroshige Yoshioka; Takashi Seto; Tamaki Fukuyama; Tomohide Tamura
Journal:  Lung Cancer       Date:  2013-07-31       Impact factor: 5.705

8.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.

Authors:  Kazuya Taniguchi; Jiro Okami; Ken Kodama; Masahiko Higashiyama; Kikuya Kato
Journal:  Cancer Sci       Date:  2008-03-04       Impact factor: 6.716

9.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis.

Authors:  M Noguchi; A Morikawa; M Kawasaki; Y Matsuno; T Yamada; S Hirohashi; H Kondo; Y Shimosato
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

10.  Limited resection and two-staged lobectomy for non-small cell lung cancer with ground-glass opacity.

Authors:  Kazuto Ohtaka; Yasuhiro Hida; Kichizo Kaga; Tatsuya Kato; Jun Muto; Reiko Nakada-Kubota; Satoshi Hirano; Yoshiro Matsui
Journal:  J Cardiothorac Surg       Date:  2013-04-24       Impact factor: 1.637

View more
  1 in total

1.  Solitary Skull Metastasis as the First Presentation of a Metachronous Primary Lung Cancer in a Survivor from Pancreatic Cancer.

Authors:  Ali Altalhy; Yazid Maghrabi; Zuhoor Almansouri; Saleh S Baeesa
Journal:  Case Rep Oncol Med       Date:  2017-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.